Mavik Articles
Actavis releases trandolapril capsules
20 October 2008
Dr Reddy's approval for generic version of Abbott drug
8 September 2008
Mylan gets US OK for generic trandolapril
5 May 2008
Sanofi and Chugai to end marketing deal
6 August 2007
Lupin's generic Mavik gets FDA OK
18 June 2007
Abbott buys rights to Aventis' tranolapril
14 June 2004
Tokyo pharma stocks - week to August 5
12 August 2002
Kos Pharmaceuticals gets $50 million boost
20 December 1999
Kos to co-promote Knoll's antihypertensives
29 July 1999
Fast Growth Seen For BASF's Pharma Unit
7 October 1998
BASF Makes Strong Start To 1998, Sales Up 7.4%
21 May 1998
BASF Not Looking To Sell Pharma Business
30 March 1998
Knoll Launches Tarka Combination In UK
11 November 1997
Knoll's Mavik Approved In USA For LVD
16 July 1997
BASF/Knoll Considering More Investment In India
20 January 1997
Knoll's Tarka Receives FDA Approval
18 November 1996
Boots Buy Boosts BASF In 1996 First Half
2 September 1996
BASF To Introduce 4 New Drugs In 1996-7
8 April 1996
BASF-Knoll Seeks Pharma Research Partner
4 March 1996
UK Industry Code of Practice: latest Report
4 March 1996
Knoll's Mavik approvable
27 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
New TRACE Data Show Sudden Death Protection
11 September 1995
Japan's Drugmakers Post Mixed End Year Results
26 June 1995
Boots Deal Strengthens Pharma At BASF
17 April 1995
Roussel-Uclaf Details Group Pipeline Plans
10 April 1995
....And Marion Merrell Dow Updates On R&D Efforts
10 April 1995
BASF Optimistic On Future With Good 1995 Start
3 April 1995
Trandolapril Shows Significant Benefit In Post-MI Patients
19 September 1994
ANTIHYPERTENSIVES FAIL TROUGH-PEAK CRITERIA
20 June 1994
LIGHT AT THE END OF THE TUNNEL FOR HOECHST?
28 March 1994
ROUND-UP OF 1993'S NEW CHEMICAL ENTITIES
31 January 1994
PROFITS DIP AT ROUSSEL UCLAF
15 November 1993
HOECHST PHARMA SALES ON THE SLIDE
25 October 1993
EARNINGS CLIMB AT ROUsSEL UCLAF
9 August 1993
KNOLL FRANCE LAUNCHES GOPTEN
1 March 1993
FIRST LAUNCH OF ROUSSEL UCLAF'S TRANDOLAPRIL
25 January 1993
Showing 1-39 of 39 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
